Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797321 | 1.00 | F10 (0.36) | F10BTKFPR2FPR1 | |
| Hydrochloric Acid SCHEMBL796773 | 0.99 | F10 (0.35) | F10BTKFPR2FPR1 | |
| SCHEMBL797320 | 0.88 | BTK (0.39) | F10BTKFPR2FPR1 | |
| Hydrochloric Acid SCHEMBL796772 | 0.87 | BTK (0.38) | F10BTKFPR2FPR1 | |
| SCHEMBL796254 | 0.87 | F10 (0.35) | F10BTK | |
| SCHEMBL796253 | 0.87 | F10 (0.35) | F10BTK | |
| Hydrochloric Acid SCHEMBL790095 | 0.86 | GPR119 (0.35) | F10BTK | |
| SCHEMBL789677 | 0.85 | BTK (0.37) | F10BTKFPR2FPR1 | |
| SCHEMBL15105593 | 0.85 | BTK (0.37) | F10BTKFPR2FPR1 | |
| SCHEMBL797271 | 0.83 | BTK (0.32) | F10BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616074-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-07-18 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012037393-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184257-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR180 | F10 3806/4885BTK 3212/4885FPR2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.